Starpharma TV
In the latest episode of Starpharma TV, CEO Dr Jackie Fairley and Jason Lickliter, Principal Investigator and Oncologist, Nucleus Network, Alfred Hospital, Melbourne, discuss Starpharma’s Phase 1 clinical trial of DEP™ docetaxel. They discuss the benefits of the drug compared to docetaxel and the positive initial results from the trial, with the dosage of the drug now exceeding the most commonly used dose for Taxotere® of 75mg/m2, with no dose limiting toxicities, including neutropenia, having been observed to date.
Seeking Alpha - Dendrimers Coming of Age: Starpharma's Star is Rising
DEP (Dendrimer Enhanced Particle) technology improves drug availability, reduces toxicity; potential for repositioning $billion drugs.
Herald Sun: Stars aligning for biotech with all the trappings
The Herald Sun's John Beveridge highlights the benefits of Starpharma's drug delivery technology, but also notes that it is "not a one-trick-pony", with its phase 3 bacterial vaginosis trials and agrochemical opportunities.
AstraZeneca to develop oncology drug using SPL’s DEP™ technology
Starpharma today announced the signing of an extension to the existing collaboration agreement with AstraZeneca to commence scale up of a dendrimer enhanced oncology molecule (“DEP™ conjugate”) for further development.